Author:
Jain Apurva,Kwong Lawrence N,Javle Milind
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Oncology
Reference57 articles.
1. Rovigatti U. Cancer modelling in the NGS era—part I: emerging technology and initial modelling. Crit Rev Oncol Hematol. 2015;96(2):274–307. doi: 10.1016/j.critrevonc.2015.05.017 .
2. Churi CR, Shroff R, Wang Y, Rashid A, Kang HC, Weatherly J, et al. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One. 2014;9(12):e115383. doi: 10.1371/journal.pone.0115383 .This article correlates clinical outcome with somatic mutations in BTC and is therefore of significance
3. Jiao Y, Pawlik TM, Anders RA, Selaru FM, Streppel MM, Lucas DJ, et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet. 2013;45(12):1470–3 .First experience with exome sequening in BTC that idnitifies mutations in chromatin modulating genes
4. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. A cancer journal for clinicians: CA; 2015.
5. Bragazzi MC, Cardinale V, Carpino G, Venere R, Semeraro R, Gentile R, et al. Cholangiocarcinoma: epidemiology and risk factors. Translational Gastrointestinal Cancer. 2011;1(1):21–32.
Cited by
102 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献